



Health Technology Review - Appeal Request	
Technology Ref:	HTA19013
Technology Name:	NeuRx DPS® - Diaphragm Pacing System
Reason for Appeal:	New evidence and explanations were provided.
Previous DOH Decision:	Disapprove
Approvals by International Bodies:	Device has FDA HDE approval
Company name:	Reyada Home Health Care Services
Agent in UAE:	Dr. Atef Elshaer
Email:	<a href="mailto:a.elshaer@reyadamgmt.com">a.elshaer@reyadamgmt.com</a>

<b>Short Description of the Technology:</b>	The initial review on this technology found Serious but well-recognized safety concerns and the evidences on efficacy was limited in both quantity and quality. The Technology Owner appealed the final decision of the US and provided new evidence.
---	---

<b>Health Technology Assessment Team Recommendation on Appeal:</b>	<b>Disapproved</b>
<b>Summary of Review:</b>	
<p>Both the Health Technology Assessment team and the sought experts in the Department of Health have reviewed the provided evidence and found out that the shared evidence was part of the initial review of this technology and it poses concerns regarding this technology such as serious adverse events, mortality and quality of life.</p> <p>With reference to Prof. Ray Onders – please note that conflict of interests were declared in the Onders studies as the primary author has intellectual property right involved with the device and equity in the company.</p> <p>After carefully considering the appeal, the HTA team stands by the latest guidance issued by the National Institute for Health and Care Excellence (NICE) in 2017 which states:  <i>“Current evidence on intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure caused by motor neurone disease suggests that there are serious long-term safety concerns. Evidence on efficacy is limited and therefore, this procedure should not be used to treat this condition”</i></p> <p>Based on this, the HTA team agreed to <b>Not Recommend</b> this technology.</p>	



Technology Image



Manual